Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-1.37 Insider Own0.70% Shs Outstand160.45M Perf Week9.71%
Market Cap3.34B Forward P/E- EPS next Y-1.01 Insider Trans-48.19% Shs Float154.10M Perf Month9.83%
Income-197.90M PEG- EPS next Q-0.36 Inst Own97.00% Short Float6.10% Perf Quarter51.75%
Sales131.30M P/S25.41 EPS this Y-79.50% Inst Trans1.20% Short Ratio4.24 Perf Half Y56.67%
Book/sh0.29 P/B71.69 EPS next Y15.10% ROA-39.90% Target Price24.88 Perf Year39.53%
Cash/sh2.23 P/C9.30 EPS next 5Y-7.30% ROE- 52W Range11.41 - 24.88 Perf YTD69.44%
Dividend- P/FCF- EPS past 5Y1.50% ROI-33.80% 52W High-16.44% Beta1.57
Dividend %- Quick Ratio4.70 Sales past 5Y18.30% Gross Margin79.10% 52W Low82.21% ATR0.86
Employees468 Current Ratio4.90 Sales Q/Q-58.10% Oper. Margin- RSI (14)54.91 Volatility4.81% 4.47%
OptionableYes Debt/Eq5.56 EPS Q/Q-189.40% Profit Margin- Rel Volume0.69 Prev Close21.50
ShortableYes LT Debt/Eq5.49 EarningsMay 09 AMC Payout- Avg Volume2.22M Price20.79
Recom1.60 SMA208.33% SMA504.40% SMA20030.38% Volume1,523,060 Change-3.30%
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Jun-13-14Reiterated MKM Partners Neutral $13
Feb-27-14Downgrade MKM Partners Buy → Neutral
Sep-27-13Reiterated MKM Partners Buy $14 → $13
Sep-12-13Initiated Cowen Outperform $17
Aug-19-11Initiated MKM Partners Buy $12
Aug-08-11Reiterated Deutsche Bank Buy $14 → $11
May-17-11Initiated Boenning & Scattergood Outperform $15
Mar-02-11Reiterated Deutsche Bank Buy $16 → $14
Feb-15-11Downgrade ThinkEquity Buy → Hold $17 → $11
Dec-03-10Initiated ThinkEquity Buy $17
Jul-29-10Reiterated Deutsche Bank Buy $17 → $16
May-11-10Downgrade Barclays Capital Overweight → Equal Weight $14
Mar-08-10Reiterated Brean Murray Buy $15 → $20
May-22-17 09:00AM  New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds PR Newswire
May-19-17 04:26PM  Bristol-Incyte Match Beats Dow's Merck In Combination Trials Investor's Business Daily
May-18-17 08:39AM  Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017 Capital Cube
08:00AM  Nektar Therapeutics Announces Data Presentations at ASCO 2017 PR Newswire
May-15-17 05:15PM  Edited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
04:16PM  ETFs with exposure to Nektar Therapeutics : May 15, 2017 Capital Cube
04:15PM  Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York PR Newswire
May-12-17 10:44AM  Nektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 09:46AM  Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1 Zacks
08:51AM  Edited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-10-17 05:18PM  The Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop Motley Fool +8.15%
May-09-17 05:50PM  Nektar reports 1Q loss Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 PR Newswire
01:15PM  Investor Network: Nektar Therapeutics to Host Earnings Call Accesswire
May-08-17 06:03PM  Nektar Therapeutics Value Analysis (NASDAQ:NKTR) : May 8, 2017 Capital Cube
May-06-17 08:41AM  Why Nektar Therapeutics Shares Fell 19.2% in April Motley Fool
May-05-17 08:14AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 5, 2017 Capital Cube
May-03-17 09:15AM  Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program PR Newswire
May-02-17 09:15AM  Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets PR Newswire
Apr-28-17 08:55AM  Biotech Surge: How To Survive In A Volatile Market Investor's Business Daily
Apr-20-17 09:10AM  Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting PR Newswire
Apr-19-17 10:44AM  How Nektar Therapeutics' Latest Drug Could Shake Up the Market for Pain Medicine Motley Fool
Apr-18-17 07:24AM  Can Drugmakers Cure the Opioid Crisis? Motley Fool
Apr-10-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Accesswire -8.01%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
07:10AM  Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue? Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Apr-04-17 09:00AM  Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire
Apr-03-17 06:49PM  Cramer's lightning round: If we get two rate hikes, this stock's a good buy CNBC
Mar-30-17 04:42PM  3 Revolutionary Drugs for Chronic Pain Motley Fool
09:23AM  Western Digital, Nektar Therapeutics And Two More Stocks Breaking Out Forbes
Mar-29-17 02:10PM  Harry Boxers five technology and biotechnology stocks to watch MarketWatch
Mar-27-17 09:00AM  Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders PR Newswire
08:24AM  Trump is tapping Chris Christie to tackle the opioid epidemic here's a fix scientists hope he'll explore Business Insider
Mar-23-17 04:43PM  Could Nektar Therapeutics Be Worth More? Motley Fool
10:59AM  AstraZeneca Stock Rising in '17: What's Working in its Favor?
Mar-22-17 12:43PM  4 Biotech Stocks to Watch
Mar-21-17 12:09PM  Nektar Therapeutics (NKTR): Heres What Just Happened Insider Monkey
10:53AM  Nektar's Pain Drug Positive in Phase III Study; Shares Gain
09:30AM  Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Accesswire
Mar-20-17 06:21PM  After-hours buzz: ESPR, NKTR, MMSI & more at CNBC +42.65%
04:41PM  Biotech Hits 11-Year High On Potential To Dethrone Oxycodone
01:41PM  Nektar Pharma Opioid Drug Shows Promise In Phase 3 at Investopedia
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
12:36PM  A new painkiller is being designed that won't get users high, and it could save thousands of lives
11:46AM  Why Nektar Therapeutics Inc. Is Rising Today at Motley Fool
10:55AM  Mondays Top Biopharma Movers
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
08:22AM  Nektar Therapeutics' stock jumps after positive results of its pain treatment drug at MarketWatch
07:38AM  NEKTAR THERAPEUTICS Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:35AM  Nektar's opioid painkiller succeeds in key late-stage study
07:30AM  NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain PR Newswire
07:30AM  Nektar Surges by Most Since 1996 After Opioid Trial Success
07:30AM  Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
Mar-07-17 01:04PM  NEKTAR THERAPEUTICS Financials
Mar-03-17 11:12AM  Nektar Therapeutics :NKTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
09:32AM  Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
09:30AM  Biotech Industry Rally Grows as Trump Vows to Cut Regulations: Today's Reports on Aurinia Pharmaceuticals and Nektar Therapeutics Accesswire
Mar-02-17 07:01PM  Nektar to Webcast Presentation at Cowen and Company's 37th Annual Health Care Conference in Boston PR Newswire +13.68%
05:08PM  Here's What's Behind Nektar Therapeutics' 20% Move Higher at Motley Fool
Mar-01-17 05:22PM  Nektar reports 4Q loss
04:37PM  NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:30PM  Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting PR Newswire
04:10PM  Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results PR Newswire
03:06PM  NEKTAR THERAPEUTICS Files SEC form 10-K, Annual Report
07:07AM  Q4 2016 Nektar Therapeutics Earnings Release - After Market Close
Feb-22-17 05:07PM  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2016 on Wednesday, March 1, 2017, After Close of U.S.-Based Financial Markets PR Newswire
Feb-18-17 07:24PM  Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium PR Newswire
Jan-25-17 10:00AM  Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma Accesswire
Jan-23-17 05:12PM  Benzinga's Option Alert Recap From January 23
Jan-10-17 04:31PM  NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
Jan-06-17 10:45AM  Nektar Therapeutics Value Analysis (NASDAQ:NKTR) : January 6, 2017
Jan-05-17 09:00AM  Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
08:15AM  Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5, 2017
Dec-28-16 10:18AM  Shire Gets FDA Approval for Label Expansion of Adynovate
Dec-27-16 01:30PM  ETFs with exposure to Nektar Therapeutics : December 27, 2016
07:00AM  Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings PR Newswire
Dec-16-16 02:05PM  ETFs with exposure to Nektar Therapeutics : December 16, 2016
Dec-15-16 03:08PM  How you can bottom-feed for stocks left behind in the Trump rally at MarketWatch
Dec-09-16 12:23PM  These small-cap stocks are expected to rise at least 31% in 2017 at MarketWatch
Dec-06-16 12:37PM  ETFs with exposure to Nektar Therapeutics : December 6, 2016
Nov-28-16 12:32PM  Is The New York Times Co (NYT) A Good Stock To Buy? at Insider Monkey -5.42%
Nov-14-16 01:59PM  ETFs with exposure to Nektar Therapeutics : November 14, 2016
09:00AM  Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London PR Newswire
Nov-10-16 10:58AM  Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
Nov-09-16 02:30PM  Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting PR Newswire
07:57AM  NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events
Nov-08-16 04:26PM  Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss
07:19AM  Coverage initiated on Nektar Therapeutics by Aegis Capital
Nov-07-16 03:23PM  Cormorant Asset Managements Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare Stocks Show Strong Returns at Insider Monkey
Nov-04-16 03:20PM  Edited Transcript of NKTR earnings conference call or presentation 3-Nov-16 9:00pm GMT
06:08AM  NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:42PM  Nektar reports 3Q loss
04:35PM  NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:10PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 PR Newswire
07:07AM  Q3 2016 Nektar Therapeutics Earnings Release - After Market Close
Oct-28-16 08:15AM  Nektar to Hold Investor & Analyst Event at 2016 Society for Immunotherapy of Cancer Annual Meeting PR Newswire
08:00AM  Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for Immunotherapy of Cancer Annual Meeting PR Newswire
Oct-27-16 04:15PM  Nektar to Announce Financial Results for the Third Quarter 2016 on Thursday, November 3, 2016, After Close of U.S.-Based Financial Markets PR Newswire
11:22AM  3 Things You Really Need to Know About Bristol-Myers Squibb's Q3 Results at Motley Fool
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale19.552,65151,82752,986May 18 08:50 PM
ROBIN HOWARD WPresident & CEOMay 16Sale19.558,388163,985160,884May 18 08:50 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale19.553,14661,504178,943May 18 08:49 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale19.553,17962,14966,091May 18 08:48 PM
Gergel Ivan P.SVP & Chief Medical OfficerMay 16Sale19.551,45028,34843,572May 18 08:46 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale19.552,95957,84860,689May 18 08:47 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale19.551,70133,25532,803May 18 08:45 PM
CHESS ROBERTDirectorMay 15Option Exercise8.375,00041,850276,623May 17 06:02 PM
CHESS ROBERTDirectorMay 15Sale19.795,00098,950271,623May 17 06:02 PM
CHESS ROBERTDirectorApr 17Option Exercise8.375,00041,850276,623Apr 19 07:30 PM
CHESS ROBERTDirectorApr 17Sale18.725,00093,600271,623Apr 19 07:30 PM
Lingnau LutzDirectorApr 07Sale20.057,000140,35023,450Apr 11 06:04 PM
KUEBLER CHRISTOPHER ADirectorApr 05Option Exercise8.3715,000125,55050,500Apr 07 06:01 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise13.70180,0002,466,000243,648Apr 07 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 05Option Exercise9.53100,000953,000134,504Apr 07 06:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 05Sale21.70100,0002,170,00034,504Apr 07 06:07 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale21.70180,0003,906,00063,648Apr 07 06:05 PM
KUEBLER CHRISTOPHER ADirectorApr 05Sale21.8815,000328,20035,500Apr 07 06:01 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMar 20Option Exercise9.96112,5001,120,875168,137Mar 22 06:04 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMar 20Sale19.69112,5002,215,12555,637Mar 22 06:04 PM
WHITFIELD ROY ADirectorMar 15Option Exercise8.3714,000117,18098,000Mar 17 06:02 PM
CHESS ROBERTDirectorMar 14Option Exercise8.375,00041,850276,623Mar 16 06:02 PM
CHESS ROBERTDirectorMar 14Sale15.415,00077,050271,623Mar 16 06:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 03Option Exercise8.5732,494278,51294,270Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 03Sale15.2132,494494,23469,270Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 02Option Exercise6.34167,5061,061,988236,776Mar 03 07:04 PM
Labrucherie Gil MSVP & Chief Financial OfficerMar 02Sale15.15167,5062,537,71669,270Mar 03 07:04 PM
Lingnau LutzDirectorFeb 21Option Exercise5.1430,000154,20060,450Feb 23 06:32 PM
Lingnau LutzDirectorFeb 21Sale13.0830,000392,40030,450Feb 23 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale13.141,96525,82055,637Feb 17 08:06 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale13.143,23742,534182,089Feb 17 08:05 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale13.148,636113,477169,272Feb 17 08:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale13.142,35930,99769,270Feb 17 08:04 PM
Gergel Ivan P.SVP & Chief Medical OfficerFeb 16Sale13.141,45719,14545,022Feb 17 08:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale13.142,19528,84263,648Feb 17 08:04 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale13.141,26116,57034,504Feb 17 08:02 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 10Option Exercise4.6545,000209,250185,326Feb 10 08:11 PM
ROBIN HOWARD WPresident & CEOFeb 08Option Exercise4.6587,500406,875265,408Feb 10 08:10 PM
ROBIN HOWARD WPresident & CEOFeb 08Sale13.0487,5001,141,000177,908Feb 10 08:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 03Option Exercise4.658,50539,548148,831Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 03Sale12.488,505106,142140,326Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 02Option Exercise4.6566,495309,202206,821Feb 06 05:20 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 02Sale12.3866,495823,208140,326Feb 06 05:20 PM
ROBIN HOWARD WPresident & CEOJan 17Option Exercise4.6587,500406,875265,408Jan 19 08:01 PM
ROBIN HOWARD WPresident & CEOJan 17Sale12.3587,5001,080,625177,908Jan 19 08:01 PM
ROBIN HOWARD WPresident & CEODec 07Option Exercise4.6587,500406,875210,408Dec 09 06:03 PM
ROBIN HOWARD WPresident & CEODec 07Sale12.2487,5001,071,000122,908Dec 09 06:03 PM
ROBIN HOWARD WPresident & CEONov 17Option Exercise4.6587,500406,875210,408Nov 18 06:12 PM
ROBIN HOWARD WPresident & CEONov 17Sale13.8787,5001,213,625122,908Nov 18 06:12 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale13.961,98627,72542,102Nov 18 06:12 PM
ROBIN HOWARD WPresident & CEONov 16Sale13.965,95883,174122,908Nov 18 06:12 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale13.961,65423,090120,326Nov 18 06:11 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale13.961,65423,09050,343Nov 18 06:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale13.961,65423,09051,129Nov 18 06:10 PM
Gergel Ivan P.SVP & Chief Medical OfficerNov 16Sale13.9684811,83826,479Nov 18 06:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale13.966709,35318,265Nov 18 06:07 PM
GREER R SCOTTDirectorOct 24Buy13.5015,000202,500121,333Oct 25 05:00 PM
ROBIN HOWARD WPresident & CEOOct 04Option Exercise4.6587,500406,875216,366Oct 06 05:07 PM
ROBIN HOWARD WPresident & CEOOct 04Sale17.0687,5001,492,750128,866Oct 06 05:07 PM
WHITFIELD ROY ADirectorSep 23Option Exercise5.2146,000239,82084,000Sep 27 05:09 PM
KUEBLER CHRISTOPHER ADirectorSep 16Sale19.137,500143,47527,500Sep 19 05:15 PM
CHESS ROBERTDirectorSep 15Option Exercise0.0015,0000263,623Sep 19 05:13 PM
GREER R SCOTTDirectorSep 15Option Exercise0.0015,000098,333Sep 19 05:14 PM
WINGER DENNIS LDirectorSep 15Option Exercise0.0015,000026,250Sep 19 05:17 PM
WHITFIELD ROY ADirectorSep 15Option Exercise0.0015,000030,000Sep 19 05:16 PM
KUEBLER CHRISTOPHER ADirectorSep 15Option Exercise0.0015,000035,000Sep 19 05:15 PM
Lingnau LutzDirectorSep 15Option Exercise0.0015,000022,450Sep 19 05:16 PM
Krivulka Joseph JDirectorSep 15Option Exercise0.0015,000050,000Sep 19 05:14 PM
CHESS ROBERTDirectorSep 15Sale19.2112,000230,520248,623Sep 19 05:13 PM
Lingnau LutzDirectorSep 15Sale19.069,000171,5407,450Sep 19 05:16 PM
ROBIN HOWARD WPresident & CEOSep 01Option Exercise4.6587,500406,875216,366Sep 02 08:03 PM
ROBIN HOWARD WPresident & CEOSep 01Sale17.8387,5001,560,125128,886Sep 02 08:03 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale17.563,31758,247121,980Aug 17 05:45 PM
ROBIN HOWARD WPresident & CEOAug 16Sale17.5611,817207,507128,866Aug 17 05:41 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale17.563,97169,73144,088Aug 17 05:42 PM
Hora ManinderSVP Pharma Dev & Mfg OpsAug 16Sale17.563,30558,03651,997Aug 17 05:38 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale17.563,30558,03652,783Aug 17 05:39 PM
Gergel Ivan P.SVP & Chief Medical OfficerAug 16Sale17.561,68529,58927,327Aug 17 05:38 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale17.561,33623,46018,935Aug 17 05:37 PM
CHESS ROBERTDirectorAug 01Option Exercise5.155,00025,750265,623Aug 03 07:01 PM
CHESS ROBERTDirectorAug 01Sale17.265,00086,300260,623Aug 03 07:01 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJul 11Option Exercise4.65100,000465,000106,809Jul 13 05:08 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJul 11Sale15.09100,0001,509,0006,809Jul 13 05:08 PM
CHESS ROBERTDirectorJul 01Option Exercise5.155,00025,750265,623Jul 05 05:21 PM
CHESS ROBERTDirectorJul 01Sale14.105,00070,500260,623Jul 05 05:21 PM
CHESS ROBERTDirectorJun 01Option Exercise5.155,00025,750265,623Jun 03 05:05 PM
CHESS ROBERTDirectorJun 01Sale15.505,00077,500260,623Jun 03 05:05 PM